Retrospective analysis of clinical outcomes after switching from Ranibizumab to Aflibercept

• Conditions: macular degeneration; H35.3; Degeneration of macula and posterior pole

• Registration Number: DRKS00010197
• Lead Sponsor: Berner Augenklinik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-04-29
• Study Completion: 2016-09-26
• Results First Posted: 2017-06-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 577

Inclusion Criteria

Patients suffering from wet AMD requiring intravitreal therapy, either newly diagnosed (treatment-naive) or pretreated with Ranibizumab in case of insufficient response or other reasons.

Exclusion Criteria

- any systemic disease potentially worsening under therapy (i.e. recent history of stroke or myocardial infarct)
- structural damage to the macula excluding functional gain
- any systemic disease interfering with local situation (i.e. Diabetes with advanced diabetic retinopathy)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of anatomical (central retinal thickness) and functional outcomes (best-corrected visual acuity) between the groups at different measurement points (start of therapy, therapy process, end of therapy with old supplement, start of therapy with new supplement, therapy process, end of therapy with new supplement). Central retinal thickness measured in µm was determined by optical coherence tomography (Spectralis TM, Heidelberg Engineering, Heidelberg, Germany), best corrected visus was determined on a logarithmic scale converted to logMAR-valus and standardized ETDRS-measurement.

Secondary Outcome Measures

Name	Time	Method
The number of intravitreal injections needed to achieve a stable retinal situation, treatment intervals